Biopsy

Global Aspiration & Biopsy Needles Market 2022-2027: Industry Trends, Regulatory Analysis, Competition Landscape, Leading Player Profiles - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 23, 2022
Oncology, Medical Devices, Health, Hospitals, Research, Science, Lung, Ultrasound, Government, Growth, Prevalence, Needle, Diagnosis, Hospital, Awareness, MRI, Breast cancer, Bone marrow, Disease, Kidney, VAB, ASC, Cancer, Adoption, USD, CNB, Biopsy, CAGR, Research, Incidence, Prostate, Medical imaging, Breast, Asia-Pacific, Stereotactic surgery

The global aspiration and biopsy needles market is valued at an estimated USD 879 million in 2021 and is projected to reach USD 1,303 million by 2027, at a CAGR of 6.8%.

Key Points: 
  • The global aspiration and biopsy needles market is valued at an estimated USD 879 million in 2021 and is projected to reach USD 1,303 million by 2027, at a CAGR of 6.8%.
  • On the basis of product, the aspiration and biopsy needles market is segmented into biopsy and aspiration needles.
  • On the basis of end-user, the aspiration and biopsy needles market is segmented into hospitals & surgical centres, ambulatory care centres, diagnostic clinics & pathology laboratories, and research & academic institutes.
  • The breast cancer segment accounted for the largest share of the aspiration and biopsy needles market in 2020.

Cleveland Diagnostics Announces Publication of Real-World Study Demonstrating the Clinical Utility of IsoPSA® for Prostate Cancer Risk Assessment

Retrieved on: 
Wednesday, February 23, 2022
Oncology, Health, Other Health, Clinical Trials, General Health, Biotechnology, Case Western Reserve University School of Medicine, SIA, Prostate cancer, American Urological Association, Medicare, Physician, Prostate-specific antigen, Diagnosis, Trial of the century, Man, LDT, MRI, Breast cancer, Health, Cancer, Lung cancer, Blood, Patient, PSA, Cleveland Clinic, Biopsy, Behavior, Medical device, Medical imaging, Oncology, Health, Other Health, Clinical Trials, General Health, Biotechnology, IsoPSA, Cleveland Diagnostics, Inc., ISOPSA, CLEVELAND DIAGNOSTICS, INC.

We expect that IsoPSA, our novel blood-based prostate cancer test, may fundamentally shift the diagnostic paradigm of prostate cancer, and improve patient care and outcomes.

Key Points: 
  • We expect that IsoPSA, our novel blood-based prostate cancer test, may fundamentally shift the diagnostic paradigm of prostate cancer, and improve patient care and outcomes.
  • Cleveland Diagnostics currently offers IsoPSA as a laboratory-developed test (LDT) conducted at its high-complexity, CLIA-certified, CAP- accredited laboratory in Cleveland, Ohio.
  • Cleveland Diagnostics, Inc. is a commercial-stage diagnostics company developing highly efficacious, lab-friendly, affordable diagnostics tests using proprietary technology to improve cancer diagnostics.
  • Its portfolio of non- invasive cancer diagnostics will be expanding from prostate cancer to breast cancer and lung cancer, and certain other diseases.

NanoString Expands Partnership with Leica Biosystems to Accelerate Spatial Discoveries with Automated Workflow

Retrieved on: 
Wednesday, February 23, 2022
Oncology, Health, Genetics, Research, Science, Biotechnology, LabCorp, RNA, Partnership, DSP, Leica Microsystems, RX, Time, BOND, IHC, NASDAQ, Diagnosis, Gene, Immunohistochemistry, Tissue, Marketing, NanoString Technologies, Biology, Translation, Heart, Pathology, In situ hybridization, Workflow, Leica Biosystems, Protein, ISH, MicroRNA, Leica, Automation, Technology, Biopsy, Pathai, Radiology, Medical imaging, Microscope, Leica Biosystems, NanoString Technologies, Inc., LEICA BIOSYSTEMS, NANOSTRING TECHNOLOGIES, INC.

Were excited to have the Leica workflow as part of our spatial biology ecosystem, said Vice President of Marketing for NanoString, Anna Berdine.

Key Points: 
  • Were excited to have the Leica workflow as part of our spatial biology ecosystem, said Vice President of Marketing for NanoString, Anna Berdine.
  • Only Leica Biosystems offers the most comprehensive portfolio that spans the entire workflow from biopsy to diagnosis.
  • NanoString, NanoString Technologies, the NanoString logo, CosMx, GeoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.
  • Leica is a registered trademark of Leica Microsystems IR GmbH and BOND RX is a trademark of Leica Biosystems Melbourne Pty Ltd. in various jurisdictions.

Patients can now benefit from same-day procedure to diagnose and treat lung cancer

Retrieved on: 
Monday, February 21, 2022
Lung, Health, Physician, Neoplasm, Prognosis, Time, Lymph, Intuition, Diagnosis, Man, Ion, Interview, MedStar Georgetown University Hospital, Disease, Lung tumor, Cancer, Hope, Interventional pulmonology, Woman, Leonardo da Vinci, Surgeon, Life, Lung cancer, Anxiety, Patient, Technology, Survival, Biopsy, Mortality, CT, Medical imaging, MD

In this new approach – Combined Robotic Assisted Thoracic Surgery (CRATS) – high-risk lung cancer patients first undergo a low dose CT scan of the lung to monitor for tumors. If a tumor is detected, the Ion robot bronchoscope is used to biopsy the lung tumor. If the lung tumor is found – through real-time biopsy – to be cancer, then the endobronchial ultrasound is used to determine if the cancer has spread to lymph nodes. If the lymph nodes are normal, then the patient undergoes surgery to remove the portion of the lung with the cancerous tumor using the DaVinci robotic video-assisted thoracic surgery system during the same anesthesia procedure. This new process – diagnosing lung cancer and removing the tumor at the same time -- saves valuable time by removing the cancer right when it is detected, thereby limiting the opportunity for spread of disease and allowing for the start of additional therapies sooner if needed. In some instances, this approach can be curative of the cancer.

Key Points: 
  • "Coupling this early diagnosis with same-day surgery for lung cancer is a win for patients," said Dr. Anderson.
  • "Given the impact of lung cancer the leading cause of cancer deaths -- this is a major step towards stopping the disease in its tracks, resulting in better outcomes and giving patients an improved chance at life."
  • In this new approach Combined Robotic Assisted Thoracic Surgery (CRATS) high-risk lung cancer patients first undergo a low dose CT scan of the lung to monitor for tumors.
  • If the lung tumor is found through real-time biopsy to be cancer, then the endobronchial ultrasound is used to determine if the cancer has spread to lymph nodes.

U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for KEYTRUDA® (pembrolizumab) to Identify Patients with Microsatellite Instability-High (MSI-H) Solid Tumors

Retrieved on: 
Monday, February 21, 2022
Research, FDA, Genetics, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Molecular medicine, American Securities, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, TMB, Twitter, Neoplasm, Merck & Co., Foundation Medicine, Immune system, Gene, Â, Gastrointestinal cancer, Organization, Oncology, Microsatellite instability, DNA repair, MSI-H, Food, Merck Sharp & Dohme Federal Credit Union, MSI, DNA, Science, FDA, Cancer, Patient, Immunotherapy, Biopsy, Merck, Pharmaceutical industry, Medical imaging, Foundation Medicine, FoundationOne CDx, FOUNDATION MEDICINE, FOUNDATIONONE CDX

FoundationOne CDx is the first and only FDA-approved companion diagnostic to aid in identifying patients with MSI-H solid tumors for whom treatment with KEYTRUDA may be appropriate.

Key Points: 
  • FoundationOne CDx is the first and only FDA-approved companion diagnostic to aid in identifying patients with MSI-H solid tumors for whom treatment with KEYTRUDA may be appropriate.
  • Not only could this approval allow more patients to benefit from KEYTRUDA, but it also underscores an important shift toward tumor-agnostic cancer care.
  • This is the third tumor agnostic companion diagnostic approval for FoundationOne CDx, which now has 26 companion diagnostic claims and two group claims across 27 targeted therapies.
  • For a full list of targeted therapies for which FoundationOne CDx is indicated as a companion diagnostic, please visit http://www.foundationmedicine.com/genomic-testing/foundation-one-cdx .

AHN Cancer Institute Becomes One of Country's First Centers to Offer Women Groundbreaking GammaPod Treatment for Early-Stage Breast Cancer

Retrieved on: 
Friday, February 18, 2022
Society, Hospital, Patient, Biopsy, Family, Woman, Quality of life, Time, Accreditation, Foundation, Allegheny, National Accreditation Program for Rectal Cancer, National Cancer Institute, National, Johns Hopkins, Colorectal cancer, Patti, Allegheny General Hospital, American College, Transport, Neoplasm, Friends, Radiation therapy, Radiation, Allegheny Health Network, Travel, Breast, Technology, Chair, Mingo Junction, Ohio, Music, MD, Breast cancer, Sidney Kimmel, AHN, Kimelman Cancer Institute, Degenerative disease, American Society for Radiation Oncology, Physician, Research, Sidney Kimmel Comprehensive Cancer Center, Cancer Institute, News, Network, Heart, Medical imaging, Dentistry, Pharmaceutical industry, Cancer

GammaPod is the world's first radiation device specifically designed for the treatment of breast cancer.

Key Points: 
  • GammaPod is the world's first radiation device specifically designed for the treatment of breast cancer.
  • GammaPod is available at only two other centers nationwide, and AHN is the first health system in Pennsylvania to offer the groundbreaking treatment to its patients.
  • Patti was AHN's first patient treated with GammaPod, which is located at AHN Cancer Institute's hub at Allegheny General Hospital.
  • Good candidates for GammaPod treatment include women with early stage breast cancer, ages 50 or older, and those who are eligible for lumpectomy.

Donor Network of Arizona Partners with Specialist Direct to Implement OPO Best Practices

Retrieved on: 
Thursday, February 17, 2022
Cloud, OPOS, Surgeon, Biopsy, Time, CEO, Solution, Donate Life America, Teleradiology, Telepathology, Transplant, Marie Cassidy, Hospital, OPO, Pathology, Specialist, DNA, Organ transplantation, Life, Organization, Medical imaging

Specialist Direct provides a best-in-class, end-to-end telepathology solution for the organ procurement organization (OPO) and transplant market.

Key Points: 
  • Specialist Direct provides a best-in-class, end-to-end telepathology solution for the organ procurement organization (OPO) and transplant market.
  • "This innovative telepathologysolution from Specialist Direct has enabled us to rapidly implement OPO biopsy best practices," commented Wendy Van Kirk, Director of Organ Recovery Services at Donor Network of Arizona.
  • "In the world of organ transplantation, time is of the essence," said W. Scott Rombach, Founder and CEO of Specialist Direct.
  • ABOUT DONOR NETWORK OF ARIZONA (DNA):Since changing its name to Donor Network of Arizona in 1993, DNA has now become the federally designated, nonprofit organ procurement organization for Arizona.

ClearPoint Neuro Reports Fourth Quarter and Full Year 2021 Preliminary Revenue Results and Guidance for Full Year 2022 Revenue

Retrieved on: 
Tuesday, February 15, 2022
Book, CNS, Patient, Biopsy, Deep brain stimulation, Quality of life, CEO, Risk, COVID, Company, Brain, U.S. Securities and Exchange Commission, Solution, Particular, Security (finance), Nasdaq, Therapy, Paper, Lists of diseases, Telephone, FDA, Growth, Research, COVID-19, GLOBE, Generic drug, Pharmaceutical industry, Animal, Medical device, Omicron, Delta

The Company also announced that its earnings call will take place on Tuesday, March 1, 2022, after the market close.

Key Points: 
  • The Company also announced that its earnings call will take place on Tuesday, March 1, 2022, after the market close.
  • Overall, we achieved record revenue and case volume across all of our segments including functional neurosurgery, biologics and drug delivery and capital and service.
  • We also met our initial guidance for both revenue and case volume despite multiple disruptions to elective procedures caused by the Delta and Omicron variants.
  • Our current cash position entering 2022 is $54.1 million and we do not at present feel the need for additional capital at any time in 2022.

Stella Diagnostics CEO Discusses Competitive Advantage in Early Cancer Detection During Audio Interview with SmallCapVoice.com

Retrieved on: 
Tuesday, February 15, 2022
Differentiable function, Patient, Biopsy, Quality of life, Cancer, Sickle Cell Anemia, a Molecular Disease, CEO, HIV disease progression rates, OTC Markets Group, Stella, Esophageal disease, OTC, GLOBE, Gastroesophageal reflux disease, Esophageal, Genomics, Proteomics, Esophageal cancer, Interview, Biotechnology, Degenerative disease, Diagnosis, Disease, Physician, SCV, Research, Next, Mayo Clinic, Oncology, Medical imaging, GERD

Stella Diagnostics is developing diagnostic tools that help physicians determine a patients risk of disease progression in precancerous indications such as Barretts esophagus.

Key Points: 
  • Stella Diagnostics is developing diagnostic tools that help physicians determine a patients risk of disease progression in precancerous indications such as Barretts esophagus.
  • Next, the interview highlights various investment considerations, including the expertise of Stella Diagnostics board of directors and executive and research and development teams.
  • This expertise is particularly weighty when you consider the competitive advantage it gives to Stella Diagnostics over its competitors.
  • For more information on this collaboration and Stella Diagnostics technology, SCV points listeners to the Companys investor page at https://www.stelladx.com/investors/investor-deck-and-news .

New Data Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy In Men with Intermediate-Risk Prostate Cancer

Retrieved on: 
Tuesday, February 15, 2022
Oncology, Medical Devices, Health, Clinical Trials, Pharmaceutical, Biotechnology, Society, Patient, Biopsy, Prostate cancer, Risk, Man, Department, HIV disease progression rates, NCCN, University Hospitals Cleveland Medical Center, Radiation therapy, National Comprehensive Cancer Network, Journal of the National Comprehensive Cancer Network, Survival, Physician, ASCO, Case Western Reserve University School of Medicine, Poster, Medical imaging

The Decipher Prostate Genomic Classifier is a prognostic biomarker that provides additional information about the aggressiveness of individual patients cancer to help physicians more accurately categorize their risk and select appropriate treatments.

Key Points: 
  • The Decipher Prostate Genomic Classifier is a prognostic biomarker that provides additional information about the aggressiveness of individual patients cancer to help physicians more accurately categorize their risk and select appropriate treatments.
  • This study enrolled men with intermediate-risk prostate cancer, and then compared clinical outcomes following randomization to two different doses of radiation therapy (70.2 Gy vs 79.2 Gy) without hormone therapy.
  • Researchers generated classifier data for each of 215 biopsy samples, then linked the data with clinical outcomes assessing multiple oncologic and survival endpoints.
  • Examples of forward-looking statements include, among others, statements regarding Veracytes belief that its Decipher Prostate genomic classifier can help guide treatment among men with intermediate-risk prostate cancer.